Searle Oncology Given Boost By Pending P&U Merger, Antibody Deal
Searle will create a platform for new oncologics development through a research collaboration with Cambridge Antibody Technology.
You may also be interested in...
Searle and Pharmacia & Upjohn are getting a head start on their proposed merger through a co-promotion deal for P&U's overactive bladder therapy Detrol.
FDA is requesting data from a Searle Phase III trial that could elucidate the cancer risk reduction that Celebrex provides for patients with familial adenomatous polyposis.
Monsanto's proposed merger of equals with Pharmacia & Upjohn hinges upon convincing shareholders that there is value in delaying the unlocking of Monsanto's ag business from the Searle pharmaceutical business.